티카그렐러

한글명:티카그렐러

카스 번호274693-27-5

상품명:TICAGRELOR

CBNumberCB51509134

분자식C23H28F2N6O4S

포뮬러 무게522.57

MOL 파일274693-27-5.mol

동의어(한글)

티카그렐러

화학적 성질

녹는점	138-140°C
끓는 점	777.6±70.0 °C(Predicted)
밀도	1.67
저장 조건	Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
용해도	메탄올(약간)에 용해됨
산도 계수 (pKa)	13.26±0.70(Predicted)
물리적 상태	고체
물리적 상태	단단한 모양
색상	흰색에서 황백색까지
optical activity	[α]/D -55 to -65°, c =0.2 in methanol
안정성	흡습성
InChIKey	OEKWJQXRCDYSHL-FNOIDJSQSA-N
SMILES	[C@@H]1(O)[C@@H](OCCO)C[C@@H](N2C3C(N=N2)=C(N[C@@H]2C[C@H]2C2=CC=C(F)C(F)=C2)N=C(SCCC)N=3)[C@@H]1O

위험 및 안전 성명

안전지침서

24/25

HS 번호

29335990

유해 물질 데이터

274693-27-5(Hazardous Substances Data)

NFPA 704:

	0
2		0

그림문자(GHS)

티카그렐러 화학적 특성, 용도, 생산

용도
Ticagrelor는 thrombotic 사건의 예방을 위해 ST 고각을 가진 심각한 관상 동맥 증후군 심근 경색을 가진 사람들에서 (예를 들면 치기 또는 심장 발작) 사용됩니다.
개요
In December 2010, the P2Y₁₂ receptor antagonist ticagrelor (also known as AZD6140) was approved in Europe for the treatment of acute coronary syndrome (ACS), a condition that covers several clinical symptoms with the potential to cause acute myocardial ischemia (MI). ADP binds to two purinergic receptors, the P2Y1 and P2Y₁₂ receptors. The action of ADP binding to the P2Y₁₂ receptor results in activation of the GP Ⅱb/Ⅲa (integrin) receptor.GP Ⅱb/Ⅲa initiates and prolongs platelet aggregation, which in turn results in the cross-linking of platelets through fibrin and finally thrombus formation. Inhibition of ADP stimulation of the P2Y₁₂ receptor has been found to be an effective strategy for managing the atherothrombotic events associated with ACS and potentially resulting from percutaneous coronary intervention (PCI, stent implantation) .
화학적 성질
White Solid
정의
ChEBI: A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for p evention of thromboembolic events in patients with acute coronary syndrome.
Clinical Use
Ticagrelor, discovered and developed by AstraZeneca, is a platelet adenosine diphosphate (ADP) P2Y12 (P2T) reversible receptor antagonist approved in the E.U. in 2010 and launched in Germany and the UK in 2011 for the treatment of patients with acute coronary syndromes (ACS). It was approved in the U.S. and Canada in 2011 following successful clinical trial results in patients with ACS which showed it to be superior to preexisting drugs for reducing death due to vascular causes. Ticagrelor is an oral drug indicated for use in combination with acetylsalicylic acid (aspirin) for the prevention of atherothrombotic events in adult patients with ACS (unstable angina, non-ST elevation myocardial infarction (NSTEMI), or ST elevation myocardial infarction (STEMI)). Unlike its competitors prasugrel and clopidogrel, which require bioactivation, ticagrelor is not a prodrug and does not require in vivo activation. It has a rapid onset of action, relatively rapid reversibility, greater potency, and exhibits consistency in platelet inhibition. Following dosing, ticagrelor reaches Cmax in about 1.5 h, with formation of a major metabolite with equipotent intrinsic activity to the parent compound.

티카그렐러 준비 용품 및 원자재

티카그렐러 공급 업체

Send Inquriy